Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	Number of Subjects Experiencing Adverse Events as a Measure of Safety, Tolerability, and Efficacy	12 Weeks	To assess the safety, tolerability, and efficacy (as measured by a 0.5%-1.5% decrease of HbA1c) of different dosages and dosing regimens of a combination of KD026 and metformin compared to placebo and metformin when administered for 3 months to subjects with type 2 diabetes mellitus
Secondary	Changes in Fasting Plasma Glucose (FPG)	12 Weeks	To assess changes in fasting plasma glucose from baseline to Week 12
Secondary	Changes in Insulin	12 Weeks	To assess changes in insulin from baseline to Week 12
Secondary	Changes in HOMA-IR	12 Weeks	To assess changes in Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) from baseline to Week 12
Secondary	Changes in Body Weight	12 Weeks	To assess changes in body weight
Secondary	Changes in AUC	12 Weeks	To assess the 6-hour time curve (AUC) for post prandial triglycerides and glucose.
Secondary	Changes in Lipids	12 Weeks	To assess changes in total cholesterol, LDL-C, HDL-C, non-HDL-C, VLDL-C, and triglyceride levels
Secondary	Changes in Blood Pressure	12 Weeks	To assess changes, if any, in baseline blood pressure associated with metabolic syndrome
Secondary	Changes in Waist Circumference	12 Weeks	To assess changes, if any, in baseline waist circumference associated with metabolic syndrome
Secondary	Changes in Body Mass Index (BMI)	12 Weeks	To assess changes, if any, in baseline measures of BMI associated with metabolic syndrome
Secondary	Changes in Plasma Levels of KD026	12 Weeks	To assess plasma levels of KD026 in all subjects
Secondary	Changes in Serum Levels of Non-Esterified Free Fatty Acids	12 Weeks	To assess the change in serum levels of non-esterified free fatty acids from baseline to Week 12

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02434744/registered

API reference For AI assistants